Sanofi-aventis Canada has entered into a licensing agreement with Intelliject for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (US and Canada).
Reportedly, in Canada, Sanofi-aventis is expected to be responsible for efforts required to obtain marketing authorisation from Health Canada, and thereafter for marketing and selling the product.
Under the terms of the agreement, Sanofi-aventis is expected to make an upfront payment. In addition, Intelliject will be eligible for future milestone payments and royalties on product sales
Hugh O’Neill, president and CEO of Sanofi-aventis Canada, said: “This agreement is in line with Sanofi-aventis’ diversification strategy. It is also a clear example of actions Sanofi-aventis Canada is taking to move away from the traditional model of a pharmaceutical company into a true patient-centric healthcare solutions provider.
“By taking a holistic approach in terms of offering not only products, but services as well as health information, and by redefining the value of such initiatives, we believe that we are setting a new standard of care in Canada”.